Christopher Scott

Christopher Scott is a Professor and Dean of Research at Queen’s University Belfast’s School of Medicine, Dentistry and Biomedical Sciences. His research focuses on nanomedicine and antibody-based therapies for cancer, inflammation, and infectious diseases. He leads the Patrick G Johnston Centre for Cancer Research and has pioneered treatments for sepsis and cancer through his lab’s work funded by agencies like the Medical Research Council and industry partners such as AstraZeneca and Immunocore.

• Academic Role: Professor & Dean of Research
• Affiliation: Queen’s University Belfast
• Lab: Patrick G Johnston Centre for Cancer Research

Research interests include nanomedicine development, antibody-drug conjugates, and cathepsin protease inhibitors. His work bridges molecular enzymology with clinical applications, leading to innovations in targeted drug delivery systems. Notable achievements include the Vice Chancellor’s Innovation Prize (2015) for sepsis nanomedicine and co-founding Fusion Antibodies Ltd (2001).

Recent projects span lung cancer protease mechanisms (R1589CNR), future medicines development (R1300CNR), and cystic fibrosis therapies (R1126CII). Over 170 publications and 27 active projects reflect his interdisciplinary impact in biomedical science.